Streetbeat News

TCNNF

Trulieve Cannabis Corp

Employees

9,000

Industry

Medicinal and Botanical Manufacturing

Open

7.21

Mkt cap

1.5B

Volume

276K

High

7.85

P/E Ratio

-10.92

52-wk high

14.50

Low

7.21

Div yield

N/A

52-wk low

4.75

Florida's legal cannabis market is estimated to reach $2.6B in sales in 2023. The state has a robust medical cannabis market with 871,459 registered patients. The top ten competitors in Florida account for 85% of dispensaries, with Surterra, AYR, Trulieve, Verano, and Curaleaf having significant shares. Green Thumb, Cannabist, Cresco, TerrAscend, and Ascend have little or no presence. Store growth outpaces patient growth, suggesting potential overexpansion. The market anticipates adult recreational use, which could double revenues, but faces legal challenges. The Viridian Cannabis Deal Tracker monitors industry trends and transactions.

Portfolio Pulse from Viridian Capital Advisors

January 30, 2024 | 3:56 pm

The article reports on the significant price movements of various marijuana stocks on January 29, 2024. Notable gainers include CordovaCann, Blueberries Medical, and 1933 Industries, with increases of 26.53%, 26.14%, and 15.88% respectively. Psychemedics, 4Front Ventures, and Canopy Growth also saw gains. On the losing side, EVIO plummeted by 99%, while Global Hemp Group and Corbus Pharmaceuticals experienced significant drops of 45.30% and 34.93%. The article was generated by Benzinga's automated content engine and reviewed by an editor.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 9:30 pm

Cannabis stocks experienced significant movements on January 24, 2024. Notable gainers included Global Hemp Group, Target Group, and Item 9 Labs, with increases of 68.40%, 47.06%, and 14.29% respectively. Trulieve Cannabis and MJ Holdings also saw gains over 11%. Corbus Pharmaceuticals and Neptune Wellness Solutions were among the NASDAQ-listed gainers. Conversely, MedMen Enterprises and EVIO suffered dramatic losses, closing down 99.99% and 98.00%. Other notable losers included Khiron Life Sciences and Cara Therapeutics. The article was generated by Benzinga's automated content engine and reviewed by an editor.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 9:30 pm

Pablo Zuanic's Q4 2023 cannabis sector report highlights state-specific market trends, with Connecticut, Ohio, Illinois, Maryland, and Rhode Island showing growth. Companies like MariMed, Verano, and Green Thumb Industries benefit from diversified state exposure. The report discusses MSO performance variations, regulatory developments, and potential political shifts that could impact the market. Key players in various states are analyzed, with the DEA's response to cannabis rescheduling being a significant upcoming event.

Portfolio Pulse from Nicolás Jose Rodriguez

January 23, 2024 | 8:38 pm

Florida Governor Ron DeSantis predicts that the state Supreme Court will approve a recreational cannabis initiative for the 2024 ballot. Despite his opposition to marijuana reform, DeSantis believes Florida voters should have their say. The initiative, backed by public support and funded by Trulieve Cannabis Corp, would allow medical cannabis companies to sell to adults but not permit home cultivation. Attorney General Ashley Moody is attempting to block the initiative, which has nearly one million signatures.

Portfolio Pulse from Maureen Meehan

January 23, 2024 | 2:12 am

Cannabis stocks experienced significant movements on January 19, 2024. EVIO led the gainers with a 9900.00% increase, while Rocky Mountain High topped the losers with a 21.62% decline. Notable gainers included Genetic Technologies, OrganiGram Holdings, and Cara Therapeutics, with increases of 42.16%, 10.72%, and 4.80% respectively. Among the losers, Corbus Pharmaceuticals and Greenlane Holdings saw declines of 4.91% and 3.32%.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 9:30 pm

West Virginia Delegate Evan Hansen introduced House Bill 4873 to legalize recreational cannabis for adults over 21. The bill follows a similar unsuccessful attempt with House Bill 2091 and comes amid suggestions by Senate President Craig Blair to use marijuana legalization as a strategy against the state's fentanyl crisis. The bill proposes a 15% excise tax and a local 6% tax to fund county and municipal needs. Multi-state medical marijuana operators like Trulieve Cannabis Corp., Columbia Care Inc., Heritage Cannabis Holding Corp, and Verano Holdings could benefit if the bill passes.

Portfolio Pulse from Nina Zdinjak

January 19, 2024 | 1:56 pm

The cannabis sector experienced bearish sentiment on January 18, 2024, with a mix of gainers and losers. Notable gainers included Genetic Technologies (GENE) and Urban-gro (UGRO), while significant losers were Aurora Cannabis (ACB), GrowGeneration (GRWG), OrganiGram Holdings (OGI), Tilray Brands (TLRY), Neptune Wellness Solutions (NEPT), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), and Village Farms International (VFF).

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 9:30 pm

The New York Cannabis Control Board approved Fiorello Pharmaceuticals, owned by Green Thumb Industries, and Citiva Medical, owned by iAnthus Capital Holdings, to transition from medical to recreational cannabis markets. Maine is considering decriminalizing small quantities of drugs, focusing on treatment over punishment. Arkansas activists submitted a ballot measure to improve medical marijuana access. Florida's medical marijuana program reports a 15% increase in patients, with a recreational legalization initiative on the horizon, supported by Trulieve Cannabis Corp.

Portfolio Pulse from Jelena Martinovic

January 17, 2024 | 2:17 pm

The article lists the cannabis stocks that experienced significant gains and losses on January 16, 2024. Notable gainers include MedMen Enterprises, C21 Investments, and 22nd Century Group, with increases of 66.67%, 19.62%, and 14.92% respectively. On the losing side, Khiron Life Sciences and Global Hemp Group saw sharp declines of 49.64% and 44.60%. The article reflects the volatility in the cannabis market and may influence investor sentiment.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 9:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.